Lead Sponsor

Hoffmann-La Roche

Age

18 - 55 years

Sex

ALL

Healthy Volunteers

No

•Diagnosis of primary progressive multiple sclerosis (according to revised McDonald criteria)
•EDSS at screening from 3 to 6.5 points
•Disease duration from onset of MS symptoms less than (\<) 15 years if EDSS greater than (\>) 5.0; \<10 years if EDSS greater than or equal to (\>/=) 5.0
•Sexually active male and female participants of reproductive potential must use two methods of contraception throughout the study treatment phase and for 48 weeks after the last dose

•History of relapsing remitting MS, secondary progressive, or progressive relapsing MS at screening
•Inability to complete an MRI (contraindications for MRI)
•Known presence of other neurologic disorders
•Known active infection or history of or presence of recurrent or chronic infection
•History of cancer, including solid tumors and hematological malignancies (except for basal cell, in situ squamous cell carcinomas of the skin and in situ carcinoma of the cervix that have been excised and resolved)
•Previous treatment with B-cell targeted therapies (e.g. rituximab, ocrelizumab, atacicept, belimumab, or ofatumumab)
•Any previous treatment with lymphocyte trafficking blockers, with alemtuzumab, anti-cluster of differentiation 4 (CD4), cladribine, cyclophosphamide, mitoxantrone, azathioprine, mycophenolate mofetil, cyclosporine, methotrexate, total body irradiation, or bone marrow transplantation
•Any concomitant disease that may require chronic treatment with systemic corticosteroids or immunosuppressants during the course of the study

Related studies

NCT05359653 · Multiple Sclerosis (MS), Multiple Sclerosis, Relapsing-Remitting, and more

NCT06138132 · Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, and more

NCT04544449 · Multiple Sclerosis, Primary Progressive

NCT03455582 · Multiple Sclerosis, Primary Progressive

NCT04918225 · Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive

A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis